CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational ...
Neoadjuvant systemic therapy leads to significant clinical and pathological response in patients with HER2-positive breast cancers. Significant predictors of pathological response include HER2 protein ...
From histopathology to multiplex immunohistochemistry and spatial transcriptomics, learn how to obtain the appropriate profiling depth to match cancer classification needs. Histological analysis of ...
High-quality histopathology reporting forms the basis for treatment decisions. The quality indicator for pathology reports from the European Society of Breast Cancer Specialists was applied to a ...
There is a low probability of success for immuno-oncology (IO) research. There is a below average likelihood-of-approval rate for oncology, usually 5.3% vs. 7.9% for all indications. The clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results